Pfizer Inc. (NYSE:PFE) announced today detailed results from ORAL Strategy, a head-to-head, noninferiority . . .
You are here
Press Release Archive
Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing . . .
Pfizer Inc. (NYSE:PFE), in partnership with Parents magazine (NYSE:MDP), announced today the . . .
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the . . .
Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and . . .
Pfizer Inc. invites investors and the general public to view and listen . . .
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration . . .
Pfizer Inc. (NYSE:PFE) today announced Phase 2 data showing that its . . .
Pfizer Inc. (NYSE:PFE) today announced that a supplemental . . .
Pfizer Inc. (NYSE:PFE) announced today that the European . . .
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food...
Pfizer Inc. (NYSE:PFE) today announced that it has received . . .
Pfizer Inc. (NYSE:PFE) today announced it will present more than 50 abstracts...
Merck KGaA, Darmstadt, Germany, and Pfizer today announced that 13 avelumab* abstracts across seven challenging tumor types will be featured at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6, 2017 in Chicago, IL. Key presentations include data for avelumab in first-line metastatic Merkel cell carcinoma (mMCC) and in previously treated metastatic urothelial carcinoma (UC), as well as results from the Phase Ib trial investigating avelumab in combination with the tyrosine kinase inhibitor axitinib, in advanced renal cell carcinoma (RCC).
Pfizer Inc. invites investors and the general public...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced...
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer...
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announce that the US Food and Drug Administration (FDA) has granted accelerated approval for BAVENCIO® (avelumab) Injection for a second indication. The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.
The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.
The Lupus Research Alliance, the world’s largest private funder of lupus research, and Pfizer Inc., the global biopharmaceutical company, announced the start of a non-interventional clinical study that will test a custom smartphone app enabling lupus patients to report on their fatigue and other symptoms in real time. Incorporating feedback from people with lupus, the new app will be evaluated through a non-interventional clinical study called VALUE (VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool), scheduled to begin at the end of this month.
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.